Institutional investors purchased a net $1.2 million shares of THRX during the quarter ended December 2013. This may signal that the smart money is gaining interest in this company as the 74.15% of the shares outstanding that institutional investors hold is among the lowest in the Biotechnology industry.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
EACM ADVISORS LLC Bought 4.1 Thousand shares of Theravance Inc
EDGE WEALTH MANAGEMENT LLC Bought 80.00 shares of Theravance Inc
WINSLOW, EVANS & CROCKER, INC. Sold 510.00 shares of Theravance Inc